Filter Results
Conditions
Locations
Treatment Type
Trial Phase
Trial Status
Paid Participation
Clear All
21 Autism Trials near Los Angeles, CA
Power is an online platform that helps thousands of Autism patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.
Stimulant Medications for ADHD in Autism Spectrum Disorder
Los Angeles, CaliforniaThis study is a pragmatic clinical trial examining the comparative effectiveness of two stimulant medications (methylphenidate and amphetamine) in the treatment of ADHD in children and adolescents with autism. Using a sequential, multiple assignment randomization trial (SMART) design the study will not only assess these two medications but also the role of an increasingly popular class of ADHD medication, the alpha-2 agonists. Findings from this study will help improve clinicians' approach to medication selection and reduce the repeated trials of multiple medications that are current standard care.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 4
Age:4 - 17
Sex:All
Key Eligibility Criteria
Disqualifiers:Unstable Medications, Others
Must Not Be Taking:ADHD Medications
500 Participants Needed
School-based Education for Autism
Los Angeles, CaliforniaThe purpose of the proposed three-site study is to test whether an educator-level implementation strategy, coaching, with or without a school-level implementation strategy, school-based teams, will maximize paraeducators' use (fidelity and sustainment) of an evidence-based social engagement intervention, Remaking Recess (RR). RR aims to improve peer related social skills for autistic students and their non-autistic peers who are socially isolated or peripheral and need support during recess.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:5+
Sex:All
Key Eligibility Criteria
Disqualifiers:Previous Remaking Recess Participation
350 Participants Needed
Smart Inhaler for Childhood Asthma
Los Angeles, CaliforniaCorrect use of daily medications containing inhaled corticosteroids is key for asthma control, yet children with intellectual and developmental disabilities (IDD) face additional barriers to proper inhaler use. Smart inhalers, a novel technology that provides guidance and immediate feedback on inhaler use techniques, have been shown to enhance correct medication administration in the typically developing pediatric population, but their effectiveness has not been evaluated on the pediatric IDD population. This study aims to investigate whether daily application of smart inhalers (1) is feasible and acceptable in the IDD population, (2) improves the rate of correct medication administration, and (3) results in improvement in lung function. This effort aims to promote better asthma management in the IDD population.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:10 - 17
Sex:All
Key Eligibility Criteria
Disqualifiers:Limited Life Expectancy, Others
Must Be Taking:Inhaled Corticosteroids
30 Participants Needed
FMT for Autism
Los Angeles, CaliforniaThe purpose of this study is to find out if transplant of fecal matter (stool), also known as fecal microbiota transplantation (FMT), from a healthy person into the intestines of children and young adults with Autism Spectrum Disorder (ASD).
For this study children between the ages of 5-17years will be recruited over 2 years. Children will be recruited who receive an ASD diagnosis using the gold-standard Autism Diagnosis Observation Schedule -2 (ADOS-2) using module 1, 2 or 3 (none, limited or no moderate expressive language). Children diagnosed with these modules of the ADOS-2 may be at greater risk for GI disorders and rigid-compulsive behaviors. Additional assessment of rigid-compulsive behaviors and social communication will be done using the Repetitive Behavioral Scales-Revised (RBS-R) and Social Responsiveness Scale-2 (SRS-2), respectively. KBIT (the Kaufman Brief Intelligence Test) is used at baseline to obtain patient IQ. Total evaluation time is approximately 90 minutes. Following baseline symptom evaluation, a medical exam will be performed to determine whether each child is expressing specific GI symptoms. In addition, parents will fill out the Questionnaire for Pediatric Gastrointestinal Symptoms- Rome III (QPGS-III). Once an ASD diagnosis is confirmed, FMT treatment will be initiated, which typically occurs within 4-6 weeks of the initial diagnosis. Half 50% of the children (n=5) will receive the equivalent of 50 g of stools from a healthy donor into the jejunum through upper endoscopy and the other 50% off children (n=5) will receive Saline solution as Placebo control through upper endoscopy.
Subjects will have a total of 5 visits within 24 weeks including phone call follow up on Day 7 after FMT.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1
Age:5 - 17
Sex:All
10 Participants Needed
ML-004 for Autism
Glendale, CaliforniaThis trial is testing the safety of a treatment called ML-004 in adolescents and adults with Autism Spectrum Disorder (ASD). The main goal is to ensure that the treatment does not cause any harmful side effects.
No Placebo Group
Trial Details
Trial Status:Enrolling By Invitation
Trial Phase:Phase 2
Age:12 - 46
Sex:All
120 Participants Needed
ML-004 for Autism Spectrum Disorder
Glendale, CaliforniaThis trial is testing a treatment called ML-004 to see if it can help improve social communication skills in adolescents and adults with Autism Spectrum Disorder (ASD). The study will involve about 150 participants to determine its effectiveness.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:12 - 45
Sex:All
Key Eligibility Criteria
Disqualifiers:Rett Syndrome, Epilepsy, Hypertension, Others
150 Participants Needed
Virtual Reality for Autism
Glendale, CaliforniaThe goal of this randomized clinical trial is to compare and learn about Virtual Reality (VR) in children with autism/Autistic children.
The main question it aims to answer is:
• Does the Floreo VR clinical product show clinical improvement in autism symptoms?
Participants will engage the VR product for twice a week for twelve weeks.
They will be randomized to either the Floreo Clinical Product or a VR Control group experience.
Researchers will compare the two groups to see if there is an effect on learning specific skills and behaviors.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:5 - 18
Sex:All
Key Eligibility Criteria
Disqualifiers:Epilepsy, Migraine, Vertigo, Others
100 Participants Needed
JASPER + PROMPT Interventions for Autism
Los Angeles, CaliforniaIn this project, the investigator will test the effect of augmenting an evidence based joint attention intervention (JASPER) with a motor-sound system intervention (PROMPT) compared to JASPER only on speech and language outcomes. The investigator will model change over a year to determine the percentage of children who cross the hurdle from single words to word combinations by Kindergarten. The proposed research will foster the understanding of the mechanisms underlying speech heterogeneity in ASD, thereby ultimately contributing to the development of more personalized, efficacious interventions.
Upon qualification to the study (after entry assessments), the child will be randomized to receive JASPER alone (play-based intervention) or JASPER plus PROMPT (both play-based and speech-based interventions). The active intervention will last for 12 weeks, 60 minute sessions twice a week. There are assessments scheduled at entry (6.5 hours), end of study (exit-2.5 hours), 3 month follow up (2 hours), and when the child turns 6 years of age (2 hours). The total time commitment per participant is 37 hours.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:48 - 66
Sex:All
Key Eligibility Criteria
Disqualifiers:Deaf, Blind, Cerebral Palsy, Others
80 Participants Needed
CBT for Autism
Culver City, CaliforniaThis trial is testing whether Cognitive Behavioral Therapy (CBT) can help children with autism better manage their emotions. The study involves 100 children who will receive either CBT with expert guidance or another form of care. The goal is to see if CBT can reduce emotional issues like irritability and anxiety in these children. Cognitive Behavioral Therapy (CBT) has been adapted and tested in various studies for treating anxiety and emotional issues in children with autism spectrum disorders (ASD).
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:6 - 14
Sex:All
Key Eligibility Criteria
Disqualifiers:Severe Psychotic Symptoms, Others
100 Participants Needed
JASPER Intervention for Autism
Los Angeles, CaliforniaThis trial is testing JASPER, a play-based therapy, on young children with autism who have limited verbal skills. The therapy uses guided play to help these children improve their social and communication abilities. JASPER (Joint Attention, Symbolic Play, Engagement, and Regulation) is a naturalistic developmental behavioral intervention that has been found effective for promoting social communication in young children with autism.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:18 - 5
Sex:All
Key Eligibility Criteria
Disqualifiers:Age Under 18 Months, Others
90 Participants Needed
DTT + JASPER for Autism
Los Angeles, CaliforniaThis trial aims to improve language skills in preschool children with autism using a structured teaching and social interaction-based learning program. The program is adjusted based on each child's progress. The goal is to help these children develop better communication skills and avoid being minimally verbal by age 6.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:36 - 59
Sex:All
Key Eligibility Criteria
Disqualifiers:Sensory Impairments, Genetic Syndromes, Others
140 Participants Needed
Training Programs for Autism
Westwood, CaliforniaThe purpose of this study is to test the effectiveness of the "Translating Evidence-based Interventions (EBI) for ASD: Multi-Level Implementation Strategy" (TEAMS) model on provider-level implementation outcomes when used to enhance provider training in two evidence-based interventions for children with autism spectrum disorder (ASD). The TEAMS- Leadership Institute (TLI) module includes training to program/school district leaders in implementation of EBI, and the TEAMS Individualized Provider Strategy for Training (TIPS) module applies Motivational Interviewing strategies to facilitate individual provider behavior change. TEAMS will be tested in combination with two clinical interventions in two community service setting contexts (1) AIM HI intervention in mental health programs and (2) CPRT intervention in schools. It is expected that the addition of TLI and / or TIPS will improve use of EBI by community providers.
No Placebo Group
Trial Details
Trial Status:Enrolling By Invitation
Trial Phase:Unphased
Age:18+
Sex:All
1206 Participants Needed
Mobile Early Social Interaction Coaching for Toddler Autism
Los Angeles, CaliforniaThe goal of this collaborative R01 is to demonstrate the therapeutic value and community-wide implementability of an early intervention (EI) platform for toddlers with autism spectrum disorder (ASD) that is completely virtual, from recruitment through intervention. This platform-Early Social Interaction Mobile Coaching (ESI-MC) deploys individual telehealth sessions with coaching and feedback to help families embed intervention in everyday activities. Specifically, the investigators will conduct an effectiveness trial of ESI-MC to address the important question of whether starting evidence-based intervention earlier leads to better outcomes than starting later. The investigators will address this question by using a modified stepped wedge design and blended implementation research to analyze data obtained with ESI-MC start at 18, 24, or 30 months. The investigators will diagnostically ascertain 240 children from a pool of 360 18-month-olds with early signs of autism, 30 in each of 8 US regions (Central and SW Florida; Atlanta, GA; suburbs of Philadelphia, PA; New York City, NY; Cincinnati, OH; Chicago, IL; Seattle, WA; and Los Angeles, CA). Research participants will be recruited using a new virtual platform-My Baby Navigator-linking a new surveillance and screening tool, an app to upload video-recorded home observations and telehealth intervention sessions, and a package of educational resources. The 240 children will be randomly assigned to one of three ESI-MC timing groups. ESI-MC will be delivered by community-based early intervention providers (EIPs) currently working within the the early intervention system in the recruitment regions. The investigators will measure child active engagement and social communication change every 6 months as the primary outcome variables. Outcome measures of developmental level, autism symptoms, and adaptive behavior will be examined to measure differential treatment effects. Maximizing the use of mobile technology, ESI-MC offers the prospect of a community-viable, scalable and sustainable treatment to improve EI services for toddlers with ASD, particularly among minority and low-resource communities.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:15 - 20
Sex:All
Key Eligibility Criteria
Disqualifiers:No Autism, Motor Impairments, Others
240 Participants Needed
Early Intervention Coaching for Infants at Risk of Autism
Los Angeles, CaliforniaThe proposed study (PETAL: Promoting Early intervention Timing and Attention to Language) aims to determine the timing of intervention among infants with Increased Likelihood for Autism (ILA; at risk for autism by virtue of having an older sibling with autism) on communication and language outcomes at 24 months. Results of this study will determine when (9 vs 12 vs 15 months), and based on which measures (brain, language, or their combination) to augment parental support with a specialized parent-mediated coaching intervention for optimal outcomes on communication and language at 24 months.
Children will be recruited at 6-8 months of age and will begin with entry assessments. All children will first begin with the MONITOR condition (using Ages \& Stages Questionnaire (ASQ-3) and activity cards. Then when the child is 9 months, they will be randomized to continue with MONITOR condition or COACH condition (incorporates JASPER intervention and Babble Bootcamp) after second set of assessments. There are a total of 6 assessment timepoints (6-8 months of age, 9 months of age, 12 months of age, 15 months of age, 18 months of age, and 24 months of age). At time points of 9months and 12 months, the child will be randomized to COACH or MONITOR conditions. Once the child is randomized to COACH condition, they will continue with that condition until they terminate the study at 24 months. At the 15 months timepoint, there will no longer be a randomization. Children that were in the MONITOR condition will change to the COACH condition until they terminate the study.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:6 - 8
Sex:All
Key Eligibility Criteria
Disqualifiers:Seizures, Surgery, Physical Disorders, Others
Must Not Be Taking:Anti-seizure Medications
140 Participants Needed
Tasimelteon for Autism and Sleep Disorders
Santa Monica, CaliforniaThis trial is testing a daily pill called tasimelteon to help children and adults with Autism Spectrum Disorder (ASD) who have trouble sleeping. The medication aims to improve sleep by helping to regulate the body's internal clock.
No Placebo Group
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:2 - 65
Sex:All
Key Eligibility Criteria
Disqualifiers:Impaired Liver Function, Pregnancy, Others
Must Not Be Taking:Sedatives, Stimulants
100 Participants Needed
Lumateperone for Autism
Sherman Oaks, CaliforniaThis is a multicenter, randomized, double-blind, placebo-controlled study in pediatric patients aged 5 to 17 years with a primary diagnosis of irritability associated with Autism Spectrum Disorder (ASD) based on Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition Text Revision (DSM-5-TR) and confirmed by the Kiddie Schedule for Affective Disorders and Schizophrenia Present and Lifetime Version (K-SADS-PL).
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:5 - 17
Sex:All
Key Eligibility Criteria
Disqualifiers:Rett Syndrome, Fragile X, Suicidal Risk, Others
Must Be Taking:ADHD Medications
174 Participants Needed
Cariprazine for Pediatric Schizophrenia
Long Beach, CaliforniaThis trial is testing the safety and effectiveness of cariprazine in children and teens with schizophrenia, bipolar I disorder, or autism. The goal is to see if the medication is safe and beneficial for use in these young patients.
No Placebo Group
Pivotal Trial
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:5 - 17
Sex:All
310 Participants Needed
Lumateperone for Irritability in Autism
West Covina, CaliforniaThis is a multicenter, randomized, double-blind, placebo-controlled study in pediatric patients aged 5 to 17 years with a primary diagnosis of irritability associated with Autism Spectrum Disorder (ASD) based on Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition Text Revision (DSM-5-TR) and confirmed by the Kiddie Schedule for Affective Disorders and Schizophrenia Present and Lifetime Version (K-SADS-PL).
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:5 - 17
Sex:All
Key Eligibility Criteria
Disqualifiers:Rett Syndrome, Fragile X, Others
Must Be Taking:ADHD Medications
174 Participants Needed
CM-AT for Autism
Orange, CaliforniaThis trial is testing a special enzyme powder called CM-AT to help children with autism digest protein better.
No Placebo Group
Pivotal Trial
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:3 - 17
Sex:All
405 Participants Needed
Pimavanserin for Autism Spectrum Disorder
Glendale, CaliforniaThis trial is testing pimavanserin, a medication that may help reduce irritability in children and teenagers with autism. The study focuses on kids aged 5 to 17 who have this symptom. Pimavanserin works by balancing brain chemicals to help them feel calmer. The goal is to see if the medication is safe and effective over time.
No Placebo Group
Prior Safety Data
Pivotal Trial
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2, 3
Age:5 - 18
Sex:All
209 Participants Needed
TB006 for Autism
Aliso Viejo, CaliforniaMultisite 14-week prospective double-blind placebo controlled parallel-group randomized clinical trial with 14-week open-label extension at the end of double-blind treatment phase for placebo subjects. Eligible subjects will be randomized within each site in 2:1 ratio to receive either TB006 or placebo treatment.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:18 - 35
Sex:All
Key Eligibility Criteria
Disqualifiers:Epilepsy, Liver Disease, Kidney Disease, Others
45 Participants Needed
Page 1 of 1+
Frequently Asked Questions
How much do Autism clinical trials in Los Angeles, CA pay?
Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.
How do Autism clinical trials in Los Angeles, CA work?
After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Autism trials in Los Angeles, CA 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length in Los Angeles, CA for Autism is 12 months.
How do I participate in a study as a "healthy volunteer"?
Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility in Los Angeles, CA several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.
What does the "phase" of a clinical trial mean?
The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.
Do I need to be insured to participate in a Autism medical study in Los Angeles, CA ?
Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.
What are the newest Autism clinical trials in Los Angeles, CA ?
Most recently, we added Lumateperone for Autism, Early Intervention Coaching for Infants at Risk of Autism and Lumateperone for Irritability in Autism to the Power online platform.